



Therapeutic Potential of Phytochemicals in Autoimmune Diseases: A Systematic Review

**Manju Bhaiyalal Shahare ^{a*}, Shriyans Reddy Yendreddy ^b,
Murshidha Shireen ^c, Bhavit Bansal ^d, Kezia William ^e,
Yatindra Kumar ^a, Sauvit S Patil ^f and Hridya Ramesh ^a**

^a Department of Life Science and Biotechnology, Chhatrapati Shivaji Maharaj University, Panvel, Maharashtra, India.

^b Department of Biotechnology, GITAM School of Technology, GITAM (Deemed to be University), Gandhi Nagar, Visakhapatnam, Andhra Pradesh, India.

^c Department of Pharmacology, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India.

^d Department of Research, Sant Hirdaram Medical College of Naturopathy and Yogic Sciences for Women, Bhopal, India.

^e Department of Pharmacy Practice, SRM College of Pharmacy, SRM University, Kattankulathur, Chennai, Tamil Nadu, India.

^f Department of Life Sciences, Ramnarain Ruia Autonomous College, Affiliated to University of Mumbai, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: <https://doi.org/10.9734/ajmah/2024/v22i91092>

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/122291>

Systematic Review Article

Received: 20/06/2024

Accepted: 28/08/2024

Published: 05/09/2024

*Corresponding author: E-mail: manju.shahare@gmail.com;

Cite as: Shahare, Manju Bhaiyalal, Shriyans Reddy Yendreddy, Murshidha Shireen, Bhavit Bansal, Kezia William, Yatindra Kumar, Sauvit S Patil, and Hridya Ramesh. 2024. "Therapeutic Potential of Phytochemicals in Autoimmune Diseases: A Systematic Review". *Asian Journal of Medicine and Health* 22 (9):80-93. <https://doi.org/10.9734/ajmah/2024/v22i91092>.

ABSTRACT

Autoimmune diseases are a significant clinical challenge worldwide. Traditional treatments often have adverse effects, leading to a growing interest in alternative therapies. This systematic review attempts a qualitative synthesis of current evidence on the therapeutic potential of phytochemicals in autoimmune diseases. The review includes randomized controlled trials (RCTs), clinical trials (CTs) and observational studies published between 2013 to 2023. Databases searched include PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL). A total of 676 studies were retrieved from various databases. We followed the PICO framework to develop the review protocol and registered on the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) with registration number INPLASY202460031.

In the context of rheumatoid arthritis, eight potential phytochemicals have been identified, including sinomenine, curcumin, flavonol quercetin, eichhornia crassipes, apocynin, β -sitosterol, tanshinone IIA, and 3'3-diindolylmethane (DIM). For multiple sclerosis, five phytochemicals - berberine, 23-Hydroxy Ursolic Acid (23-OH UA), forskolin, sulforaphane (SFN), and moringin - have shown effectiveness. Flavonol quercetin and portulaca oleracea exhibit potential for treating type 1 diabetes. Furthermore, curcumin and quercetin have demonstrated potential activity against oral lichen planus (OLP). Anatabine has shown effectiveness against Hashimoto's Thyroiditis, while thuja occidentalis is a potential option for the treatment of Inflammatory Bowel Disease (IBD). Additionally, agave tequilana shows potential efficacy against Systemic Lupus Erythematosus (SLE). These natural compounds offer promising alternative or adjunctive treatments with fewer adverse effects compared to conventional therapies. Nevertheless, rigorous clinical validation is necessary to translate these findings into clinical practice and establish standardized guidelines for their use in autoimmune disease management.

Keywords: Autoimmune diseases; phytochemicals; clinical trials; In vitro animal studies; systematic review.

1. INTRODUCTION

"Autoimmune diseases (AIDs) encompass a wide range of disorders characterized by an abnormal immune response against the body's own tissues, leading to persistent inflammation and tissue damage" [1]. "These conditions can affect individuals of all ages, with a higher prevalence in women. One of the key immune responses in these diseases is the production of autoantibodies, which serve as important biomarkers for the diagnosis, categorization, and monitoring of disease activity" [2]. "AIDs include but are not limited to, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes and psoriasis" [3].

"Despite the variation in their clinical manifestations, the underlying pathology of autoimmune diseases is largely driven by dysregulation of the immune system. This dysregulation often involves a complex interplay of genetic, environmental, and immunological factors, leading to the development of autoimmunity and sustained inflammatory processes" [2,4].

Conventional treatments for autoimmune diseases primarily involve the use of immunosuppressive drugs such as corticosteroids, methotrexate, and biologics [5]. While these treatments can effectively reduce disease activity and control symptoms, they are associated with significant adverse effects, including increased susceptibility to infections, liver toxicity, oxidative stress and cardiovascular complications [6-10]. In addition, not every patient responds in the same way to these medications, and some patients may develop resistance, over time. This highlights the need for alternative or adjunctive treatments that can deliver therapeutic benefits with fewer side effects [10].

In recent years, a significant number of studies have investigated the therapeutic properties of phytochemicals [11]. These bioactive compounds derived from plants, have attracted significant attention from researchers and the pharmaceutical industry because of their potential therapeutic applications in various chronic diseases, including AIDs [12,13]. For example, compounds such as curcumin from turmeric, resveratrol from grapes, and quercetin

from onions and apples are well known for their anti-inflammatory, antioxidant, and immunomodulatory properties, which make them promising candidates for the treatment and management of AIDs [14]. The therapeutic potential of these phytochemicals in autoimmune diseases has been supported by a growing body of preclinical and clinical evidence [15]. However, their effectiveness and safety profile in the treatment of AIDs remain to be fully elucidated [16].

This systematic review qualitatively synthesizes current evidence on the therapeutic potential of phytochemicals in AIDs, with a focus on their efficacy and safety. The primary objectives of this review are to evaluate the efficacy of phytochemicals in improving disease activity, inflammatory markers, and quality of life in individuals with autoimmune diseases. Moreover, this review will compare the effectiveness of phytochemicals with that of conventional treatments and assess the safety profile of these bioactive compounds. The significance of this review lies in its potential to identify alternative therapeutic options for patients with autoimmune diseases.

2. METHODS

This systematic review explores the therapeutic potential of different phytochemicals against autoimmune diseases. We followed the PICO (population, intervention, comparison, outcome) framework to develop the review protocol. The protocol was registered on the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) with registration number INPLASY202460031 [17,18].

2.1 Search Strategy

A comprehensive search strategy was used for each database, using a combination of Medical Subject Headings (MeSH) terms and keywords related to autoimmune diseases and phytochemicals along with Boolean operators. An example of search strategy for PubMed is provided: ("Autoimmune Diseases" OR "autoimmune disease" OR "rheumatoid arthritis" OR "multiple sclerosis" OR "lupus" OR "autoimmune" AND ("Phytochemicals" OR "phytochemical*" OR "curcumin" OR "resveratrol" OR "quercetin" OR "plant extract*" AND ("therapeutic use" OR "therapeutic potential" OR "treatment" OR "therapy" OR "efficacy").

2.2 Study Characteristics

The experimental studies to be included were randomized controlled trials (RCTs), clinical trials (CTs), cohort studies, case-control studies, and observational studies published between 2013 and 2023. Only fully open-access studies with a detailed and scientific methodology to measure the therapeutic potential of phytochemicals are included.

The databases searched included PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL).

2.3 Quality Assessment/Risk of Bias Analysis

The risk of bias was assessed via the Cochrane risk of bias tool for RCTs, the Newcastle-Ottawa Scale for observational studies and SYRCLE's risk of bias tool for animal studies. Two reviewers independently assessed the risk of bias, and disagreements were resolved by consensus.

3. RESULTS AND DISCUSSION

A total of 545 studies were retrieved from various databases, with an additional 131 studies sourced from references and other literature. After careful screening and eligibility assessment, 19 studies were found to be suitable for inclusion in the review. These selected studies encompassed four randomized control trials, fourteen in vitro animal studies, and one observational study (see Fig. 1, which shows the PRISMA flow diagram of the study selection process (Tables 1, 2 and 3 summarize the studies selected).

A variety of phytochemicals have been evaluated for their therapeutic potential against several autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, type 1 diabetes, oral lichen planus, inflammatory bowel disease, systemic lupus erythematosus, and Hashimoto's thyroiditis. The potential phytochemicals identified in this review include sinomenine, curcumin, flavonol quercetin, Eichhornia crassipes, apocynin, β -sitosterol, tanshinone IIA, 3'-3'-diindolylmethane (DIM), berberine, 23-hydroxy ursolic acid (23-OH UA), forskolin, sulfuraphane (SFN), moringin, portulaca oleracea, anatabine, Thuja occidentalis and agave tequilana (see Table 4).




Fig. 1. PRISMA 2020 flow diagram for systematic reviews, which included searches of databases, registers and other sources




Fig. 2. Illustration of autoimmune diseases identified and potential phytochemicals for their treatment

Table 1. Summary of selected randomized control trials for review

First Author, Year	Autoimmune disease	Phytochemical	Type of comparator	Dosage	Route of administration	Findings
Li et al., 2018 [19]	Rheumatoid Arthritis (RA)	Sinomenine	methotrexate	10 to 50 µg/mL per day	~	Sinomenine regulated and reduced RA activity in clinical settings.
Khan et al., 2022 [20]	Rheumatoid Arthritis	Curcumin	~	180 mg/day	Oral tablets	Curcumin was found to be more effective in patients with rheumatoid arthritis when given with strengthening exercises.
Kia et al., 2020 [21]	Oral lichen planus (OLP)	Curcumin	Prednisolone	80 mg/day	Oral tablets	Oral Curcumin is an alternative therapy for OLP in patients with contraindicated Corticosteroids
Schmeltz et al., 2013 [22]	Hashimoto's thyroiditis	Anatabine	Placebo	0.17 to 0.25 mg/kg/day	Oral tablets	Anatabine-treated patients had a significant reduction in absolute serum thyroglobulin antibody levels from baseline by study end relative to those receiving placebo

Table 2. Summary of selected in vitro animal studies for review

First Author, Year	Autoimmune disease	Animal Used for Experiment	Phytochemical	Type of comparator	Dosage (mg/kg/day)	Route of administration	Findings
Mosawy et al., 2014 [23]	Type 1 diabetes	C57BL/6 mice	Flavonol quercetin	Placebo (citrate buffer)	6	Intraperitoneal injection	Treatment with quercetin significantly reduced diabetes-induced platelet hyperaggregability in response to platelet agonist stimulation.
Tavaf et al., 2023 [24]	Experimental autoimmune encephalomyelitis	C57BL/6 mice	Berberine	~	10 -30	oral gavage	Berberine has a protective effect on disease development and alleviating disease status

First Author, Year	Autoimmune disease	Animal Used for Experiment	Phytochemical	Type of comparator	Dosage (mg/kg/day)	Route of administration	Findings
	(EAE) [Animal model of multiple sclerosis]						in EAE
Asmis et al., 2024 [25]	Experimental Autoimmune Encephalomyelitis (EAE) in a Murine Model of Multiple Sclerosis	C57BL/6 mice	23-Hydroxy ursolic acid (23-OH UA)	low-calorie maintenance diet	~	Oral	Dietary 23-OH represents an effective oral adjunct therapy for the prevention and treatment of relapsing-remitting Multiple Sclerosis.
Sattar et al., 2023 [26]	Rheumatoid arthritis	Sprague–Dawley rats	Eichhornia crassipes	piroxicam	100	Sub plantar injection	E. crassipes suppressed arthritis progression, reduced paw edema, and improved ankle joint histopathological and haematological analyses confirmed reduction of rheumatoid arthritis (RA).
Aman et al., 2023 [27]	Rheumatoid arthritis	Wistar rats	Apocynin gel	Diclofenac sodium gel	30	Topical Administration	Study proved the therapeutic activity of the APO-hybrid NPs-based gel formulation against Complete Freund's Adjuvant-induced rheumatoid arthritis (CFA-induced RA) in rats
Rakhshandeh et al., 2022 [28]	Type 1 diabetes	Wistar rats	Portulaca oleracea	~	100 -300	oral gavage	Portulaca oleracea extract significantly ameliorated streptozotocin-induced diabetes and other parameters that were elevated.
Kapoor et al., 2022 [29]	Multiple sclerosis	Wistar rats	Forskolin	Fingolimod (FNG), Simvastatin (SIM), Donepezil	40	orally	FSK therapy restored brain mitochondrial-ETC complex enzymes and neurotransmitter levels while decreasing inflammatory cytokines and

First Author, Year	Autoimmune disease	Animal Used for Experiment	Phytochemical	Type of comparator	Dosage (mg/kg/day)	Route of administration	Findings
				(DON), and Memantine (MEM)			oxidative stress markers. The Luxol fast blue (LFB) stain results further indicate FSK's neuroprotective potential in preventing oligodendrocyte death.
Zhang et al., 2020 [30]	Rheumatoid arthritis	Wistar rats	β -sitosterol solid lipid nanoparticles	Indomethacin	2.5 and 25	orally	β -sitosterol solid lipid nanoparticles showed the antiarthritic effect via suppression of NF-kB and activation of HO-1/Nrf-2 pathway.
Du et al., 2020 [31]	Rheumatoid arthritis	C57BL/6 mice	Tanshinone IIA	sodium carboxymethyl cellulose	300	oral gavage	The effects of Tan IIA on RA can be attributed to its influence on different signalling pathways, including MAPK, AKT/mTOR, HIF-1, and NF-kB. The compound Tan IIA has great therapeutic potential for RA treatment.
Stan et al., 2019 [32]	Inflammatory bowel disease	CD1 mice	Thuja occidentalis	Ethanol	5, 25 and 50	oral gavage	Study proved that administration of 25 or 50 mg Thuja occidentalis inhibited the inflammatory process induced by TNBS in the intestine
Du et al., 2019 [33]	Rheumatoid arthritis	C57BL/6 mice	3'-Diindolylmethane (DIM)	Sodium carboxymethyl cellulose suspension	10	oral gavage	DIM inhibited proliferation, migration and invasion of RA-FLSs and reduce proinflammatory factors induced by TNF- α in vitro by blocking MAPK and AKT/mTOR pathway and

First Author, Year	Autoimmune disease	Animal Used for Experiment	Phytochemical	Type of comparator	Dosage (mg/kg/day)	Route of administration	Findings
							prevent inflammation and knee joint destruction in vivo, which suggests that DIM might have therapeutic potential for RA.
Yoo et al., 2019 [34]	Experimental Autoimmune Encephalomyelitis (EAE) in a Murine Model of Multiple Sclerosis	C57BL/6 mice	Sulforaphane (SFN)	phosphate-buffered saline	50	oral	The SFN treatment showed anti-inflammatory and antioxidative effects in the EAE mice. SFN has neuroprotective effects via anti-inflammatory processing, so it could be a new therapeutic or nutritional supplement for MS.
Gutiérrez Nava et al., 2017 [35]	Systemic lupus erythematosus	BALB/c mice	Agave tequilana	Methotrexate and prednisone	10	oral	A. tequilana contains active compounds with the capacity to modify the evolution of the systemic autoimmunity type-SLE on a murine model.
Giacoppo et al., 2016 [36]	Experimental Autoimmune Encephalomyelitis (EAE) in a Murine Model of Multiple Sclerosis	C57BL/6 mice	Moringin	~	10	Intraperitoneal injection	Study has found that Moringin can reduce apoptosis by decreasing the expression of the Fas ligand and cleaved caspase 9. At the same time, it increases the expression of antioxidant Nrf2 in EAE mice. These results provide an interesting discovery, identifying Moringin as a modulator of the Wnt-β-catenin signalling cascade and a potential new therapeutic target for the treatment of MS.

Table 3. Summary of the selected observational studies for review

First Author,Year	Autoimmune disease	Phytochemical	Type of comparator	Dosage	Route of administration	Findings
Zhao et al., 2022 [37]	Oral lichen planus	Quercetin		40 µM	~	In vitro experiments revealed that quercetin affects the Th1/Th2 balance by targeting IL-6 and IFN-γ to regulate the immune system for treating OLP. Quercetin significantly impacts the apoptosis and migration of T lymphocytes in OLP patients.

Table 4. List of autoimmune diseases and potential phytochemicals identified as having therapeutic effects

Autoimmune Disease	Potential Phytochemical
Rheumatoid Arthritis (RA)	Sinomenine Curcumin Flavonol Quercetin Eichhornia Crassipes Apocynin β -Sitosterol Tanshinone IIA 3'3-Diindolylmethane (DIM)
Multiple Sclerosis (MS)	Berberine 23-Hydroxy Ursolic Acid (23-OH UA) Forskolin Sulforaphane (SFN) Moringin
Type 1 Diabetes	Flavonol Quercetin Portulaca Oleracea
Oral Lichen Planus (OLP)	Curcumin Quercetin
Hashimoto's Thyroiditis	Anatabine
Inflammatory Bowel Disease (IBD)	Thuja Occidentalis
Systemic Lupus Erythematosus (SLE)	Agave Tequilana

These findings indicate the promising role of phytochemicals in modulating immune responses, reducing inflammation, and potentially offering safer alternatives to conventional treatments.

Phytochemicals exhibit their potential as therapeutic agents against autoimmune diseases by modulating various biological mechanisms and pathways in the body. For instance, quercetin influences the immune system by acting on IL-6 and IFN- γ , making it a promising candidate for treating oral lichen planus (OLP). Studies have shown that quercetin significantly impacts apoptosis and the migration of T lymphocytes in OLP patients [37].

In the context of Experimental Autoimmune Encephalomyelitis (EAE), moringin has been demonstrated to reduce apoptosis by decreasing the expression of Fas ligand and cleaved caspase 9, while simultaneously increasing the expression of the antioxidant Nrf2. Similarly, β -sitosterol has emerged as a potential phytochemical against rheumatoid arthritis, exhibiting anti-arthritic activity through the suppression of NF-kB and activation of the HO-1/Nrf-2 pathway. Tanshinone IIA, another phytochemical with therapeutic potential for rheumatoid arthritis, modulates several signaling pathways, including MAPK, AKT/mTOR, HIF-1, and NF-kB.

It is important to note that the studies reviewed employed different methodologies to assess the activity of these phytochemicals against their respective diseases. Despite the lack of uniformity in the approaches used, the studies consistently concluded that phytochemicals hold promise as potential therapeutic agents for these conditions.

We believe that this systematic review will assist future research endeavours as it has already qualitatively synthesized and presented the available evidence. Future research efforts should prioritise practical applications and human trials to advance the development of these phytochemicals as viable treatments for public use.

4. CONCLUSION

This systematic review provides convincing evidence supporting the utilization of phytochemicals in the management of autoimmune diseases. In the context of rheumatoid arthritis, eight potential phytochemicals have been identified, including sinomenine, curcumin, flavonol quercetin, Eichhornia crassipes, apocynin, β -sitosterol, tanshinone IIA, and 3'3-diindolylmethane (DIM). Five phytochemicals, namely, berberine, 23-hydroxyursolic acid (23-OH UA), forskolin, SFN

(SFN), and moringin, have been shown to be effective against multiple sclerosis. The flavonols quercetin and Portulaca oleracea have potential for the treatment of type 1 diabetes.

Additionally, curcumin and quercetin have demonstrated potential activity against oral lichen planus (OLP). Anatabine has been shown to be effective against Hashimoto's thyroiditis, and Thuja occidentalis is a potential option for the treatment of inflammatory bowel disease (IBD). Furthermore, Agave Tequilana is another phytochemical with potential efficacy against systemic lupus erythematosus (SLE). Compared with conventional therapies, these natural compounds offer promising alternative or adjunctive treatments with fewer adverse effects.

However, rigorous clinical validation is necessary to translate these findings into clinical practice and establish standardized guidelines for their use in autoimmune disease management.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) declare that no generative AI tech such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of manuscripts. For language correction and readability improvement, Curie was used.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENT

We would like to express our gratitude to DELBIODESK-Research and Innovations and Mr. Akshay V.P. for their valuable guidance and technical support in the successful completion of this study. We disclose that no funding assistance was received for this study from any source.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Megha KB, Joseph X, Akhil V, Mohanan PV. Cascade of immune mechanism and consequences of inflammatory disorders. *Phytomedicine*. 2021;91:153712.
2. Pisetsky DS. Pathogenesis of autoimmune disease. *Nature reviews. nephrology*. 2023;19(8): 509–524. available:<https://doi.org/10.1038/s41581-023-00720-1>
3. wang I, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. *Journal of Internal Medicine*. 2015;278(4):369-395.
4. Javierre BM, Hernando H, Ballestar E. Environmental triggers and epigenetic deregulation in autoimmune disease. *Discovery Medicine*. 2011;12(67):535-545.
5. Chandrashekara S. The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. *Indian journal of pharmacology*. 2012;44(6):665-671.
6. Hegde SS, Agarwal SVS. Biomarkers of oxidative stress and their clinical relevance in type 2 diabetes mellitus patients: A systematic review. *Cureus*. 2024;16(8): e66570. DOI:10.7759/cureus.66570 Accessed on: (August 10, 2024)
7. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. *Current Opinion in Rheumatology*. 2023;15(5):528-534.
8. De Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. *American Journal of Kidney Diseases*. 2000;35(2): 333-346.
9. Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. *Otolaryngologic Clinics of North America*. 2010;43(4):753-768.
10. Hussain Y, Khan H. Immunosuppressive drugs. *Encyclopedia of infection and immunity*. 2022;726.
11. Pandohee J, Kyereh E, Kulshrestha S, Xu B, Mahomoodally MF. Review of the recent developments in metabolomics-based phytochemical research. *Critical Reviews*

- in Food Science and Nutrition. 2023;63 (19):3734-3749.
12. Roy A, Khan A, Ahmad I, Alghamdi S, Rajab BS, Babalghith AO, Islam MR. Flavonoids a bioactive compound from medicinal plants and its therapeutic applications. *BioMed Research International*. 2022;2022(1):5445291.
 13. Alamgir ANM, Alamgir ANM. Biotechnology, *In vitro* production of natural bioactive compounds, herbal preparation, and disease management (treatment and prevention). *Therapeutic use of medicinal plants and their extracts: Phytochemistry and Bioactive Compounds*. 2018;2:585-664.
 14. Zaid AN, Al Ramahi R. Depigmentation and anti-aging treatment by natural molecules. *Current Pharmaceutical Design*. 2019;25(20):2292-2312.
 15. Sharma S, Naura AS. Potential of phytochemicals as immune-regulatory compounds in atopic diseases: A review. *Biochemical Pharmacology*. 2020;173: 113790.
 16. Rasmi TR, Attavar Pavan Chand, Hydrose, Sona P, Kotian M, Shashidhar, Delna NS. Antibiofilm and antibacterial properties of herbal extracts as alternatives to current treatment approaches: A Narrative review. *Asian Journal of Medicine and Health*. 2024;22(2):12-22. ISSN 2456-8414. Available:<https://doi.org/10.9734/ajmah/2024/v22i2979>
 17. Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: A systematic review. *Journal of the Medical Library Association: JMLA*. 2018;106(4):420-431. Available:<https://doi.org/10.5195/jmla.2018.345>
 18. Shahare MB, Yendreddy SR, Shireen M, Bansal B, Kezia K, Kumar Y, Patil S, Ramesh H. Inplasy protocol. 2024;202460031. DOI:10.37766/inplasy2024.6.0031
 19. Liu W, Zhang Y, Zhu W, Ma C, Ruan J, Long H, Wang Y. Sinomenine Inhibits the Progression of Rheumatoid Arthritis by Regulating the Secretion of Inflammatory Cytokines and Monocyte/Macrophage Subsets. *Front Immunol*. 2018;9:2228. DOI: 10.3389/fimmu.2018.02228. PMID: 30319663; PMCID:PMC6168735.
 20. Khan MK, Khan IA, Liaquat A. Therapeutic potential of curcumin with and without strengthening exercises in improving rheumatoid arthritis. *Journal of the College of Physicians and Surgeons--Pakistan: JCPSP*. 2022;32(12):1640–1643. Available:<https://doi.org/10.29271/jcpsp.2022.12.1640>
 21. Kia SJ, Basirat M, Mortezaie T, Moosavi MS. Comparison of oral nano-curcumin with oral prednisolone on oral lichen planus: A randomized double-blinded clinical trial. *BMC complementary medicine and therapies*. 2020;20(1):328. Available:<https://doi.org/10.1186/s12906-020-03128-7>
 22. Schmeltz LR, Blevins TC, Aronoff SL, Ozer K, Leffert JD, Goldberg MA, Horowitz BS, Bertenshaw RH, Troya P, Cohen AE, Lanier RK, Curtis Wright I. Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: A randomized controlled clinical trial. *The Journal of Clinical Endocrinology and Metabolism*. 2013;99(1):E137. Available:<https://doi.org/10.1210/jc.2013-2951>
 23. Mosawy S, Jackson DE, Woodman OL, Linden MD. The flavonols quercetin and 3',4'-dihydroxyflavonol reduce platelet function and delay thrombus formation in a model of type 1 diabetes. *Diabetes and Vascular Disease Research*. 2014;11(3):174-181. DOI:10.1177/1479164114524234
 24. Tavaf MJ, Soltanmohammadi A, Zargarani S, Yazdanpanah E, Sadighimoghaddam B, Yousefi B, Sameni HR, Haghmorad D. Berberine promotes immunological outcomes and decreases neuroinflammation in the experimental model of multiple sclerosis through the expansion of Treg and Th2 cells. *Immunity, inflammation and disease*. 2023;11(1):e766. Available:<https://doi.org/10.1002/iid3.766>
 25. Asmis R, Medrano MT, Chase Huizar C, Griffith WP, Forsthuber TG. Dietary supplementation with 23-hydroxy ursolic acid reduces the severity and incidence of

- Acute Experimental Autoimmune Encephalomyelitis (EAE) in a Murine Model of Multiple Sclerosis. *Nutrients*. 2024;16(3):348.
26. Sattar S, Shabbir A, Shahzad M, Akhtar T, Ahmad A, Alnasser SM, Riaz B, Karimullah S, Ahmad A. *Eichhornia crassipes* Ameliorated Rheumatoid Arthritis by Modulating Inflammatory Cytokines and Metalloproteinase Enzymes in a Rat Model. *Medicina (Kaunas, Lithuania)*. 2023;59(9):1594.
Available: <https://doi.org/10.3390/medicina59091594>
27. Aman RM, Zaghoul RA, Elsaed WM, Hashim IIA. *In vitro-in vivo* assessments of apocynin-hybrid nanoparticle-based gel as an effective nanophytomedicine for treatment of rheumatoid arthritis. *Drug Delivery and Translational Research*. 2023;13(11):2903–2929.
Available: <https://doi.org/10.1007/s13346-023-01360-5>
28. Rakhshandeh H, Rajabi Khasevan H, Saviano A, Mahdinezhad MR, Baradaran Rahimi V, Ehtiati S, Etemad L, Ebrahimzadeh-Bideskan A, Maione F, Askari VR. Protective effect of portulaca oleracea on streptozotocin-induced type I Diabetes-associated reproductive system dysfunction and inflammation. *Molecules (Basel, Switzerland)*. 2022;27(18):6075.
Available: <https://doi.org/10.3390/molecules27186075>
29. Kapoor T, Mehan S, Suri M, Sharma N, Kumar N, Narula AS, Alshammari A, Alasmari AF., Alharbi M, Assiri MA, Kalfin R. Forskolin. an adenylyl cyclase/camp/creb signalling activator restoring myelin-associated oligodendrocyte destruction in experimental ethidium bromide model of multiple sclerosis. *Cells*. 2022;11(18):2771.
Available: <https://doi.org/10.3390/cells11182771>
30. Zhang F, Liu Z, He X, Li Z, Shi B, Cai F. β -Sitosterol-loaded solid lipid nanoparticles ameliorate complete Freund's adjuvant-induced arthritis in rats: Involvement of NF- κ B and HO-1/Nrf-2 pathway. *Drug Delivery*. 2020;27(1):1329–1341.
<https://doi.org/10.1080/10717544.2020.1818883>
31. Du H, Wang Y, Zeng Y, Huang X, Liu D, Ye L, Li Y, Chen X, Liu T, Li H, Wu J, Yu Q, Wu Y, Jie L. Tanshinone IIA Suppresses proliferation and inflammatory cytokine production of synovial fibroblasts from rheumatoid arthritis patients induced by TNF- α and Attenuates the Inflammatory Response in AIA Mice. *Frontiers in Pharmacology*. 2020;11:568.
Available: <https://doi.org/10.3389/fphar.2020.00568>
32. Stan MS, Voicu SN, Caruntu S, Nica IC, Olah NK, Burtescu R, Balta C, Rosu M, Herman H, Hermenean A, Dinischiotu A. Antioxidant and anti-inflammatory properties of a thuja occidentalis mother tincture for the treatment of ulcerative colitis. *Antioxidants (Basel, Switzerland)*. 2019;8(9):416.
Available: <https://doi.org/10.3390/antiox8090416>
33. Du H, Zhang X, Zeng Y, Huang X, Chen H, Wang S, Wu J, Li Q, Zhu W, Li H, Liu T., Yu Q, Wu Y, Jie L. A novel phytochemical, DIM, inhibits proliferation, migration, invasion and tnf- α induced inflammatory cytokine production of synovial fibroblasts from rheumatoid arthritis patients by targeting MAPK and AKT/mTOR Signal Pathway. *Frontiers in Immunology*. 2019;10:1620.
Available: <https://doi.org/10.3389/fimmu.2019.01620>
34. Yoo IH, Kim MJ, Kim J, Sung JJ, Park ST, Ahn SW. The anti-inflammatory effect of sulforaphane in mice with experimental autoimmune encephalomyelitis. *Journal of Korean medical science*, 2019;34(28):e197.
Available: <https://doi.org/10.3346/jkms.2019.34.e197>
35. Gutiérrez Nava ZJ, Jiménez-Aparicio AR, Herrera-Ruiz ML, Jiménez-Ferrer E. Immunomodulatory effect of agave tequilana evaluated on an autoimmunity like-SLE model induced in BALB/c mice with pristane. *Molecules (Basel, Switzerland)*. 2017;22(6):848.
Available: <https://doi.org/10.3390/molecules22060848>
36. Giacoppo S, Soundara Rajan T, De Nicola GR, Iori R, Bramanti P, Mazzon E. Moringin activates Wnt canonical pathway by inhibiting GSK3 β in a mouse model of experimental autoimmune encephalomyelitis. *Drug Design, Development and Therapy*. 2016;10:3291–3304.

Available:<https://doi.org/10.2147/DDDT.S110514>

37. Zhao Z, Wang L, Zhang M, Zhou C, Wang Y, Ma J, Fan Y. Reveals of quercetin's therapeutic effects on oral lichen planus

based on network pharmacology approach and experimental validation. Scientific Reports. 2022;12.

Available:<https://doi.org/10.1038/s41598-022-04769-z>

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/122291>